Pharmacokinetic drug interactions in palliative care: Focus on opioids

Journal of Palliative Medicine

Volumn 12, Issue 11, 2009, Pages 1043-1050

  Strouse, Thomas B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; CODEINE; CYTOCHROME P450; DIAZEPAM; FENTANYL; GEFITINIB; HYDROCODONE; HYDROMORPHONE; IMATINIB; KETOCONAZOLE; LAPATINIB; LORAZEPAM; METHADONE; MORPHINE; NALOXONE; NIFEDIPINE; NORTRIPTYLINE; OPIATE; OXAZEPAM; OXYCODONE; OXYMORPHONE; PAROXETINE; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; SUNITINIB; TRAMADOL; VERAPAMIL;

AGITATION; CANCER PAIN; CANCER PALLIATIVE THERAPY; DRUG ANTAGONISM; DRUG METABOLISM; ELECTROCARDIOGRAPHY MONITORING; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUCURONIDATION; HEALTH SERVICE; HUMAN; METABOLIC CAPACITY; NONHUMAN; POLYPHARMACY; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW;

ANALGESICS, OPIOID; DRUG INTERACTIONS; GUIDELINES AS TOPIC; HUMANS; PALLIATIVE CARE;

EID: 70450206025     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.0127     Document Type: Review

References (39)

1. Foley KM: Pain assessment and cancer pain syndromes. In: Doyle D, Hanks FWC, MacDonald N (eds): Oxford Textbook of Palliative Medicine, 2nd ed. Oxford: Oxford Medical Publications 1997, pp. 310-331.
2. Luddington L, Cox S, Higginson I: The need for palliative care for patients with non-cancer diseases: A review of the evidence. Int J Palliat Nurs 2001;5:221-226.
3. Bruera E, MacMillan K, Hanson J. MacDonald RN: Palliative care in a cancer center: Results in 1984 versus 1987. J Pain Symptom Manage 1990;5:1-5.
4. Emmanuel LL, von Gunten CF, Farris F: The Education for Physicians on End of Life Care (EPEC) Curriculum. Chicago IL: 1999.
5. Meyers FJ, Linder J: Simultaneous care: Disease treatment and palliative care throughout illness. J Clin Oncol 2003; 21:1412-1415.
6. National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for Quality Palliative Care, 2nd ed. Pittsburgh,PA:2009.www. nationalconsensusproject.org/guideline.pdf (Last accessed July 20, 2009).
7. Kharasch ED: Opioid analgesics. In: Levy R, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds): Metabolic Drug Interactions. Philadelphia: Lippincott Williams & Wilkins, 2000, pp. 297-320
8. Holmquist G: Opioid metabolism and effects of cytochrome P450. Pain Med 2009;10:S20-S29.
9. Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivates. Theory and clinical reality, part I. Psychosomatics 2003;44:167-171.
10. Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivates. Theory and clinical reality, Part II. Psychosomatics 2003;44:515-520.
11. Armstrong SC, Wynn GH, Sandson NB: Pharmacokinetic drug interactions of synthetic opiate analgesics. Psychsomatics 2009;50:169-176.
12. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G: Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-1722.
13. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM, Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 1990;265:3975.
14. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH: Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effects, and side effects. Eur J Clin Pharmacol 1996;51:289-295.
15. Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK: Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J Clin Psychopharmacol 2002;22:326-329.
16. Sindrup SH, Hoffman U, Asmussen J, Mikus G, Brøsen K, Nielsen F, Ingwersen SH, Broen Christensen C: Impact of quinidine on plasma and CSF concentration of codeine and morphine after codeine intake. Eur J Clin Pharmacol 1996;49: 503-509.
17. Osborne R, Joel S, Trew D, Slevin M: Morphine and meatolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite M6G. Clin Pharmacol Ther 1990;47:12-19.
18. Christup LL: Morphine metabolites. Acta Anaesthesiol Scand 1997;41:116-122.
19. Osborne R, Joel S, Grebenik K, Trew D, Slevin M: The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993;54:158-167.
20. Säwe J, Pacifici GM, Kager L, von Bahr C, Rane A: Regioselective glucuronidation of morphine and interactions with ebenzodiazepines in human liver. Adv Pain Res Ther 1986;8:57-64.
21. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, Yamada H. Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: Dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 2006;34:1277-1282.
22. Otton SV, Shadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM: CYP2D6 Phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Phmarcol Ther 1993;54;463-472.
23. Heiskanen T, Olkkola KT, Kalso E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64:603-611.
24. Schneider E, Brune K: Opioid activity and distribution of fentanyl metabolties. Arch Pharmacol 1086;334:267-274.
25. Kharasch ED, Whittington D, Hoffer C: Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology 2004;101:729-737.
26. Wright AW, Nocente ML, Smith MT: Hydromorphone-3-glucuronide: Biosynthesis and preliminary pharmacological evaluation. Life Sci 1998;63:401-411.
27. Endo Pharmaceuticals. Oxymorphone Hydrochloride (Opana) Product Information. Chadd's Ford, PA: 2006.
28. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brøsen K, Ossig J, Sindrup SH: The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to to CYP2D6. Anesth Analges 2006;102:146-150.
29. Laugeson S, Enggard TP, Pedersen RS, Sindrup SH, Brøsen K: Paroxetine, a cytochrome P450 sD6 inhibitor, dimished the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005 77;312-323.
30. Bruera E, Sweeney C: Methadone use in cancer patients with pain: A review. J Palliat Med 2002;5:127-138.
31. de Vos JW, Geerlings PJ, Van den Brink W, Ufkes JG, Van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995;48:361-366.
32. Lotsch J, Skarke, C, Tegeder I, Geisslinger G: Drug interactions with patient controlled analgesia. Clin Pharmacokinet 2002;41:31-37.
33. Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM: The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Therap 1998;63:655-662.
34. Kharasch ED, Walker A, Whittington D, Hoffer C, Shelels Bedynek P: Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009;101:158-168.
35. fda.gov/search?client=FDA&site=medwatch&output=xml-no-dtd&lr= &getfields=*&proxystylesheet=FDA&q=methadone&sa.x= 10&sa.y=7
36. Aureta K, Goucke CR, Ilett KF, Page-Sharp M, Boyd F, Ooh TE: Pharmacokinetics and pharacodynamcis of methadone enantiomers in hospice patients with cancer pain. Ther Drug Monit 2006;28:359-366.
37. Shaiova L, Berger A, Blinderman CD, Bruera E, Davis MP, Derby S, Inturrisi C, Kalman J, Mehta D, Pappagallo M, Perlov E: Consensus guideliens on parenteral methadone use in pain and palliative care. Palliat Support Care 2008;6:165-176.
38. Weschules DJ, Bain KT, Richeimer S: Actual and Potential Drug Interactions Associated with Methadone. Pain Med 2008;3:315-344.
39. Ferrari A, Coccia CP, Bertolini A, Sternier E. Methadone-Metabolism, pharmacokinetics, and interactions. Pharmacol Res 2004;50:551-559.